Time to Buy UnitedHealth-Heavy ETFs?

UnitedHealth (UNH) shares surged 12% on August 15, 2025, following Berkshire Hathaway's disclosure of a new $1.57 billion stake, alongside fresh positions from Appaloosa and Lone Pine Capital. This institutional confidence emerges despite UNH reporting a significant Q2 earnings miss, driven by rising medical expenses and a deteriorating medical care ratio, which led to a sharp cut in its 2025 adjusted EPS guidance to at least $16 from a prior $26-$26.50. However, the stock's 47.5% decline over the past year has left it trading at a discounted 10.83x forward P/E, significantly below its 5-year median, suggesting the institutional investments are likely a bet on valuation and the underlying strength of its health benefits and Optum segments, despite near-term operational headwinds.

Analysis

UnitedHealth Group (UNH) presents a dichotomous investment profile, characterized by significant new institutional interest clashing with deteriorating near-term fundamentals. The disclosure of a $1.57 billion stake by Berkshire Hathaway, alongside new positions from Appaloosa and Lone Pine Capital, catalyzed a 12% stock price increase on August 15, 2025, signaling a potential vote of confidence from prominent value investors. This interest is likely driven by valuation; following a 47.5% decline over the past year, UNH trades at a 10.83x forward P/E, a substantial discount to its five-year median of 19.2x. However, the company's operational performance shows significant stress. UNH missed second-quarter earnings estimates, driven by a 13.2% year-over-year increase in first-half operating expenses and a 430 basis point deterioration in its medical care ratio to 89.4%. This pressure prompted a severe reduction in full-year guidance, with adjusted net EPS now projected to be at least $16, a steep cut from the previous $26-$26.50 range and below the 2024 figure of $27.66. Furthermore, projected 2025 operating cash flows of $16 billion are down sharply from $24.2 billion in 2024. While top-line growth remains robust, with revenues in the health benefits and Optum segments growing 17% and 6.8% respectively in Q2, the sharp margin contraction and guidance revision have resulted in a Zacks Rank #5 (Strong Sell) and an average analyst price target that implies a slight decline from its current price.

Key Decisions for Investors

• Given the significant new investment from Berkshire Hathaway and a forward P/E of 10.83x, far below the historical median, long-term value investors may see the current share price as an attractive entry point, betting on a recovery beyond near-term margin pressures.
• Investors should exercise caution due to the severe cut in 2025 adjusted EPS guidance to at least $16 from over $26, a deteriorating Medical Care Ratio of 89.4%, and a Zacks Strong Sell rating, all of which signal considerable fundamental headwinds.
• Monitor the company's Medical Care Ratio in subsequent earnings reports, as a stabilization or improvement in this key profitability metric will be a critical catalyst for a sustained share price recovery.
• For those seeking to mitigate single-stock risk while maintaining sector exposure, a diversified strategy using UNH-heavy ETFs like IHF or XLV could be a prudent alternative to a direct investment.